Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health, Inc. (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company. This news page aggregates press releases and announcements related to OPKO’s pharmaceutical, diagnostics and collaboration activities, offering a focused view of how the company communicates business developments to the market.
Readers can find news about OPKO’s quarterly business highlights and financial results, as reported in its earnings press releases and accompanying conference call information. These updates typically summarize segment performance across pharmaceuticals and diagnostics, and describe notable transactions such as the sale of certain BioReference Health oncology and related clinical assets to Labcorp.
The news feed also reflects OPKO’s biopharmaceutical pipeline and research collaborations. Items include disclosures from ModeX Therapeutics, an OPKO Health company, on multispecific antibody programs like MDX2001 and MDX2004, as well as collaboration agreements with partners such as Regeneron Pharmaceuticals and Merck. In addition, OPKO reports on joint work with Entera Bio on oral GLP-1/glucagon and GLP-2 tablet candidates and on regulatory milestones for diagnostics such as the 4Kscore® Test.
Investors and observers can follow OPKO’s participation in healthcare investor conferences, where management holds one-on-one meetings and public discussions, as well as announcements about share repurchase authorizations and capital structure transactions. By reviewing this page regularly, users can see how OPKO presents its operational progress, collaborations and diagnostics initiatives over time.
OPKO Health, Inc. (NASDAQ: OPK) will report its financial results for Q1 2022 on May 9, 2022, after U.S. market close. The company's senior management will discuss the results and provide financial guidance during a live conference call at 4:30 PM ET. Participants can pre-register for the call and access a webcast on OPKO's Investor Relations page. A replay will be available until May 16, 2022. For further information about OPKO's operations and market position, visit their official website.
GeneDx, Inc. has published research highlighting the importance of genomic data sharing for identifying gene-disease relationships. This initiative, facilitated through GeneMatcher, has resulted in over 200 new associations of disease-gene links in just three years. The findings were published in Human Mutation, demonstrating how collaboration between clinicians and researchers can accelerate diagnosis for rare diseases. GeneDx's extensive database of over 300,000 clinical exomes plays a crucial role in these developments, significantly impacting patient diagnostics and advancing precision medicine.
Saol Therapeutics has announced a collaboration with GeneDx to identify patients with Pyruvate Dehydrogenase Complex Deficiency (PDCD), a rare mitochondrial disease affecting fewer than 300 children annually in the U.S. The partnership aims to increase recruitment for a Phase 3 clinical trial testing dichloroacetate (DCA), which has Orphan Product designation from the FDA for congenital lactic acidosis. The trial is crucial as PDCD currently lacks FDA-approved treatments. Dr. Peter Stacpoole emphasizes the importance of the collaboration for effective patient recruitment.
OPKO Health, Inc. (NASDAQ: OPK) announced its fourth quarter 2021 financial results with total revenues of $401.3 million, down from $494.6 million in Q4 2020. The company reported a net loss of $73.8 million, or $0.11 per share, compared to net income of $32.3 million a year prior. Key highlights include NGENLA® receiving regulatory approvals in multiple countries and RAYALDEE® launched in Germany. OPKO has entered a definitive agreement for Sema4 to acquire GeneDx for a potential total consideration of $623 million.
OPKO Health, Inc. (NASDAQ: OPK) is set to release its financial results for the quarter ended December 31, 2021, post-market on February 24, 2022. The company will also provide a business update and financial guidance during a conference call at 4:30 p.m. Eastern on the same day. Investors can pre-register for the call or access it via a live audio webcast. The call aims to discuss operating metrics and future outlook. For more details about OPKO's strategies and market position, visit their website.
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) received EU marketing authorization for NGENLA™ (somatrogon), a long-acting growth hormone replacement therapy for children with growth hormone deficiency (GHD). This innovative treatment reduces injection frequency from daily to weekly, potentially enhancing patient adherence and quality of life. The approval is based on the positive results from a Phase 3 study demonstrating NGENLA's non-inferiority to GENOTROPIN® (somatropin) in height velocity. NGENLA is now available across all EU states, Iceland, Norway, and Liechtenstein.
OPKO Health, Inc. (NASDAQ: OPK) announces the launch of RAYALDEE® in Germany, marking the first international release of the extended-release calcifediol product. Vifor Fresenius Medical Care Renal Pharma (VFMCRP), OPKO's partner, plans to expand the rollout across 11 European countries with Switzerland next in line. RAYALDEE is indicated for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency, addressing a significant market opportunity in Europe, where about 26 million people are affected.
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) received a Complete Response Letter (CRL) from the FDA concerning their Biologics License Application for somatrogon, a once-weekly treatment for pediatric growth hormone deficiency (GHD). Pfizer will collaborate with the FDA to address the feedback. Despite the setback, somatrogon has gained approvals in several countries, including Japan, Canada, and Australia. The European Commission decision is expected soon. The companies remain committed to advancing somatrogon and addressing unmet medical needs in GHD.
OPKO Health and Pfizer Japan announced the approval of NGENLA®, a once-weekly treatment for children with growth hormone deficiency (GHD), approved by Japan's Ministry of Health. This long-acting recombinant human growth hormone reduces injection frequency from daily to weekly, enhancing convenience for patients. The approval is based on positive outcomes from two Phase 3 clinical studies, showing comparable efficacy to GENOTROPIN. NGENLA® was well tolerated, marking a significant development in pediatric GHD treatment.
OPKO Health, Inc. (NASDAQ: OPK) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 10-13, 2022. The company will engage in one-on-one meetings with investors and host a virtual fireside chat on January 12 at 3:00 p.m. ET. The chat will be webcast live, with a replay available on OPKO's website.
OPKO is a biopharmaceutical and diagnostics firm focused on leveraging its proprietary technologies for growth in rapidly expanding markets.